-
-
-
-
-
-
-
Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
-
-
-
-
-
-
-
Milestone Pharmaceuticals (MIST) Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
-
-
-
-
-
-
-
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
-
-
15,434 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

